A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Japanese Healthy Adult Subjects
Latest Information Update: 11 Oct 2024
At a glance
- Drugs E 6742 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Co Ltd
- 14 Jul 2021 Status changed from recruiting to completed.
- 05 Mar 2021 Planned End Date changed from 31 May 2021 to 21 Jun 2021.
- 05 Mar 2021 Planned primary completion date changed from 31 May 2021 to 21 Jun 2021.